Actionable secondary findings in arrhythmogenic right ventricle cardiomyopathy genes: impact and challenge of genetic counseling
Author(s) -
Angela Abicht,
Ulrike Schön,
Andreas Laner,
Elke HolinskiFeder,
Isabel Diebold
Publication year - 2021
Publication title -
cardiovascular diagnosis and therapy
Language(s) - English
Resource type - Journals
eISSN - 2223-3660
pISSN - 2223-3652
DOI - 10.21037/cdt-20-585
Subject(s) - medicine , genetic counseling , genetic testing , sudden cardiac death , population , disease , medical genetics , cardiomyopathy , genetics , bioinformatics , cardiology , gene , heart failure , biology , environmental health
Comprehensive genetic analysis yields in a higher diagnostic rate but also in a higher number of secondary findings (SF). American College of Medical Genetics and Genomics (ACMG) published a list of 59 actionable genes for which disease causing sequence variants are recommended to be reported as SF including 27 genes linked to inherited cardiovascular disease (CVD) such as arrhythmia syndromes, cardiomyopathies and vascular and connective tissue disorders. One of the selected conditions represented in the actionable gene list is the arrhythmogenic right ventricle cardiomyopathy (ARVC), an inherited heart muscle disease with a particularly high risk of sudden cardiac death (SCD). Since clinical symptoms are frequently absent before SCD, a genetic finding is a promising option for early diagnosis and possible intervention. However, the variant interpretation and the decision to return a SF is still challenging.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom